Stay Updated with the Latest AC Immune S.A. ACIU News in Real Time
Find ACIU news now at Meyka AI. Stay informed with the latest AC Immune S.A. stocks updates, including price news, market analysis, and expert insights.
Walmart Great Value Berry Recall Expands to 16 States Over E. Coli Risk
Walmart Great Value Organic Triple Berry Blend recalled in 16 states due to E. coli O145 contamination. Check lot code 6040 01-6. No illnesses linked to the product yet.
Study: Babies Born Under Sugar Rationing Face Lower Cancer Risk Decades Later
Study of 64,761 UK adults shows those exposed to sugar rationing in infancy had lower cancer risk decades later. Researchers found reductions in liver, prostate, lung, rectal, and breast cancers.
Moderna and Merck’s Melanoma Vaccine Jumps Stocks on Phase 3 Win
Moderna and Merck’s personalized mRNA cancer vaccine succeeded in Phase 3 melanoma trials, reducing disease recurrence. MRNA jumped 8.9% and MRK rose 2.4% on the announcement.
Australia’s First Mainland Mammal Dies From H5N1 as Bird Flu Spreads Across Six States
Australia confirms first H5N1 bird flu death in mainland mammal: a long-nosed fur seal. The virus has now spread to six states with 298 detected events, threatening iconic species including black swans and endangered sea lions.
Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21
Moderna stock jumps 122% after announcing its personalized mRNA melanoma vaccine met Phase 3 trial goals. The vaccine reduced cancer recurrence and spread when combined with Merck’s Keytruda.
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20
Moderna jumps 177% and Merck rises 12% after their mRNA cancer vaccine meets Phase 3 endpoints for melanoma. The combo reduced cancer recurrence and spread in over 1,100 patients.
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12%
Moderna jumped 177% and Merck rose 12% after announcing the first Phase 3 win for an mRNA cancer vaccine. The personalized treatment reduced melanoma recurrence risk significantly.